Cargando…

Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer

OBJECTIVES: A small subset of patients treated with immune checkpoint inhibitors manifest atypical patterns of response, the so-called pseudoprogression (PP) and hyperprogression (HP). Their prevalence in urothelial (UC) and renal cancer (RCC) remains, to date, mostly uninvestigated. Therefore, we a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soria, Francesco, Beleni, Andrea I., D’Andrea, David, Resch, Irene, Gust, Kilian M., Gontero, Paolo, Shariat, Shahrokh F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Topic Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208670/ https://www.ncbi.nlm.nih.gov/pubmed/29549485 http://dx.doi.org/10.1007/s00345-018-2264-0

Ejemplares similares

Update on systemic treatment of upper tract urothelial carcinoma: a narrative review of the literature
por: Gust, Kilian M., et al.
Publicado: (2021)

PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients: Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer
por: Resch, Irene, et al.
Publicado: (2018)

Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis
por: Yanagisawa, Takafumi, et al.
Publicado: (2023)

Intravesical bacillus Calmette-Guérin for bladder cancer: are all the strains equal?
por: D’Andrea, David, et al.
Publicado: (2019)

The rational and benefits of the second look transurethral resection of the bladder for T1 high grade bladder cancer
por: Soria, Francesco, et al.
Publicado: (2019)

Molecular markers in bladder cancer
por: Soria, Francesco, et al.
Publicado: (2018)

An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer
por: Soria, Francesco, et al.
Publicado: (2018)

Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery
por: Abufaraj, Mohammad, et al.
Publicado: (2016)

Impact of sex on outcomes after surgery for non-muscle-invasive and muscle-invasive bladder urothelial carcinoma: a systematic review and meta-analysis
por: Mori, Keiichiro, et al.
Publicado: (2022)

Association of super-extended lymphadenectomy at radical cystectomy with perioperative complications and re-hospitalization
por: D’Andrea, David, et al.
Publicado: (2019)

Diagnostic accuracy, clinical utility and influence on decision‐making of a methylation urine biomarker test in the surveillance of non‐muscle‐invasive bladder cancer
por: D'Andrea, David, et al.
Publicado: (2019)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
por: Kasparian, Saro, et al.
Publicado: (2020)

En bloc resection of bladder tumour: the rebirth of past through reminiscence
por: Teoh, Jeremy Yuen-Chun, et al.
Publicado: (2023)

Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma: a multi-institutional study
por: Abufaraj, Mohammad, et al.
Publicado: (2016)

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
por: Shen, Pan, et al.
Publicado: (2021)

Predictive models and prognostic factors for upper tract urothelial carcinoma: a comprehensive review of the literature
por: Mbeutcha, Aurélie, et al.
Publicado: (2016)

Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses
por: Zang, Hongjing, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor-Induced Cerebral Pseudoprogression: Patterns and Categorization
por: Urban, Hans, et al.
Publicado: (2022)

Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy
por: Moschini, Marco, et al.
Publicado: (2017)

Hyperprogression in Pediatric Melanoma Metastatic to the Breast Treated with a Checkpoint Inhibitor
por: Bernal Vaca, Laura, et al.
Publicado: (2019)

How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
por: Denis, Morgane, et al.
Publicado: (2020)

Genomic alterations associated with pseudoprogression and hyperprogressive disease during anti-PD1 treatment for advanced non-small-cell lung cancer
por: Zhou, Rui, et al.
Publicado: (2023)

Medical practice and placebo response: an inseparable bond?
por: Jilch, Sandra, et al.
Publicado: (2020)

Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know
por: Camelliti, Simone, et al.
Publicado: (2020)

Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics
por: Refae, Sadal, et al.
Publicado: (2020)

Hyperprogressive Disease In Cervical Small Cell Carcinoma Treated By Immune Checkpoint Inhibitor
por: Xu, Zihan, et al.
Publicado: (2019)

Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma
por: Schuiveling, M., et al.
Publicado: (2020)

Hyperprogressive Disease in Malignant Carcinoma With Immune Checkpoint Inhibitor Use: A Review
por: Liu, Xiaojun, et al.
Publicado: (2022)

Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy
por: Wei, Zhanqi, et al.
Publicado: (2022)

Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors
por: Mönch, Sebastian, et al.
Publicado: (2023)

Performance of clinical risk scores and prediction models to identify pathogenic germline variants in patients with advanced prostate cancer
por: Rebhan, Katharina, et al.
Publicado: (2023)

Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer
por: Wang, Zhenghang, et al.
Publicado: (2021)

MRI as a screening tool for prostate cancer: current evidence and future challenges
por: Würnschimmel, Christoph, et al.
Publicado: (2022)

Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis
por: Schuettfort, Victor M., et al.
Publicado: (2020)

Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer
por: Sweis, Randy F., et al.
Publicado: (2018)

Building bridges in urothelial carcinoma to face common challenges
por: Mathieu, Romain, et al.
Publicado: (2016)

Contemporary concepts and controversies in the diagnosis and management of urothelial carcinoma
por: Shariat, Shahrokh F., et al.
Publicado: (2016)

The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy
por: Sabio, Erich, et al.
Publicado: (2019)

Author Correction: Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics
por: Refae, Sadal, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gsglphuhmqo5vdm217oopll344